NKIND Trademark

Trademark Overview


On Thursday, February 2, 2023, a trademark application was filed for NKIND with the United States Patent and Trademark Office. The USPTO has given the NKIND trademark a serial number of 97777750. The federal status of this trademark filing is FIRST EXTENSION - GRANTED as of Wednesday, June 19, 2024. This trademark is owned by ImmunityBio, Inc.. The NKIND trademark is filed in the Pharmaceutical Products, Computer & Software Services & Scientific Services, and Medical & Beauty Services & Agricultural Services categories with the following description:

Pharmaceutical preparations and substances for the treatment of immunologic dysfunction, cancer, autoimmune diseases, and infectious diseases for scientific, clinical, medicinal, and therapeutic purposes; pharmaceutical preparations and substances for the prevention of immunologic dysfunction, cancer, autoimmune diseases, and infectious diseases; pharmaceutical and biological preparations for use in targeted immunotherapy for the treatment and prevention of immunologic dysfunction, cancer, autoimmune diseases, and infectious diseases; biological preparations for the treatment and prevention of immunologic dysfunction, cancer, autoimmune diseases and infectious diseases in the fields of immunotherapy, and immuno-oncology; anti-infectives for medical use for the treatment and prevention of immunologic dysfunction, autoimmune diseases, and infectious diseases

Medical services; medical information; providing a website featuring medical information in the fields of immunotherapy; providing a website featuring medical information in the fields of oncology, cancer, immune-oncology, autoimmune diseases, and infectious diseases; providing medical information relating to pharmaceuticals, oncology, cancer, immune-oncology, immunotherapy, autoimmune diseases, and infectious diseases

Medical and pharmaceutical research and development services; medical and scientific research in the fields of pharmaceuticals, oncology, cancer, immune-oncology, immunotherapy, autoimmune diseases, and infectious diseases; product development in the fields of pharmaceuticals, oncology, cancer, immune-oncology, immunotherapy, autoimmune diseases, and infectious diseases
nkind

General Information


Serial Number97777750
Word MarkNKIND
Filing DateThursday, February 2, 2023
Status730 - FIRST EXTENSION - GRANTED
Status DateWednesday, June 19, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 12, 2023

Trademark Statements


Goods and ServicesPharmaceutical preparations and substances for the treatment of immunologic dysfunction, cancer, autoimmune diseases, and infectious diseases for scientific, clinical, medicinal, and therapeutic purposes; pharmaceutical preparations and substances for the prevention of immunologic dysfunction, cancer, autoimmune diseases, and infectious diseases; pharmaceutical and biological preparations for use in targeted immunotherapy for the treatment and prevention of immunologic dysfunction, cancer, autoimmune diseases, and infectious diseases; biological preparations for the treatment and prevention of immunologic dysfunction, cancer, autoimmune diseases and infectious diseases in the fields of immunotherapy, and immuno-oncology; anti-infectives for medical use for the treatment and prevention of immunologic dysfunction, autoimmune diseases, and infectious diseases
Goods and ServicesMedical services; medical information; providing a website featuring medical information in the fields of immunotherapy; providing a website featuring medical information in the fields of oncology, cancer, immune-oncology, autoimmune diseases, and infectious diseases; providing medical information relating to pharmaceuticals, oncology, cancer, immune-oncology, immunotherapy, autoimmune diseases, and infectious diseases
Goods and ServicesMedical and pharmaceutical research and development services; medical and scientific research in the fields of pharmaceuticals, oncology, cancer, immune-oncology, immunotherapy, autoimmune diseases, and infectious diseases; product development in the fields of pharmaceuticals, oncology, cancer, immune-oncology, immunotherapy, autoimmune diseases, and infectious diseases

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, February 21, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateTuesday, February 21, 2023
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateTuesday, February 21, 2023
Primary Code044
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameImmunityBio, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSan Diego, CA 92121

Party NameImmunityBio, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSan Diego, CA 92121

Trademark Events


Event DateEvent Description
Tuesday, February 7, 2023NEW APPLICATION ENTERED
Tuesday, February 21, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, November 1, 2023ASSIGNED TO EXAMINER
Tuesday, November 7, 2023EXAMINERS AMENDMENT -WRITTEN
Tuesday, November 7, 2023EXAMINERS AMENDMENT E-MAILED
Tuesday, November 7, 2023NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Tuesday, November 7, 2023EXAMINER'S AMENDMENT ENTERED
Tuesday, November 7, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, February 6, 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, November 22, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, December 12, 2023PUBLISHED FOR OPPOSITION
Tuesday, December 12, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Wednesday, June 19, 2024SOU TEAS EXTENSION RECEIVED
Wednesday, June 19, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, June 19, 2024SOU EXTENSION 1 GRANTED
Wednesday, June 19, 2024SOU EXTENSION 1 FILED